Sign In
Buy SNGX
$0.483
-0.266 (-35.48%)
At Close: Jun 03, 2026
Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development
07:00am, Monday, 28'th Dec 2020
PRINCETON, N.J., Dec. 28, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
Soligenix, Inc. COVID-19 Vaccine Candidate, CiVax, Could Be a More Viable Alternative to Moderna and Pfizer
08:30am, Wednesday, 09'th Dec 2020
New York, New York--(Newsfile Corp. - December 9, 2020) - The COVID-19 pandemic has been one of the most significant "black swan" events in recent history. As of early December 2020, around 1.5 mill
Soligenix: One Approvable Drug And Another With Phase 3 Read Out Soon - $55M Valuation Won't Last
12:38am, Monday, 26'th Oct 2020
Positive Phase 3 data reported on Oct. 22, solidifies the approvability of SGX301 for CTCL treatment, an estimated $250M annual revenue opportunity, yet SNGX's valuation is only ~$55M. SGX942 for oral
